Clinical trials: LET
Cytomegalovirus Infection
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants…
- Trial name
- NCT03930615
- Testing
- Letermovir
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Lacerations, Pain, Procedural
Comparison of Two Application Techniques for LET Gel
Comparison of anesthetic efficacy of Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel (LET) applied three times for 10 minutes each time vs.
- Conditions
- Lacerations, Pain, Procedural, LET
- Trial name
- NCT04203225
- Testing
- LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Appendicitis
Laparoscopic Versus Open Appendectomy? Let the Patient Decide
This protocol examines choice where it pertains to choosing between two standard methods for appendectomy, laparoscopic or open procedures, and the affect that "cost" of the appendectomy has upon choice.
- Trial name
- NCT01738750
- Testing
- Cost Information Included
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center